The Nasdaq biotechnology index has fallen more than 14 percent in January, and large pharmaceutical companies have also taken a hit. Moderna’s stock fell 37 percent on the S&P 500, and BioNTech is down 37 percent, too.
Investors are favoring safe bets in industries like energy and banking and dumping stocks in high-risk, high-reward companies in the technology, biotech and healthcare sectors.
Potential regulatory challenges such as potential drug pricing reform and a tougher crackdown on mergers may also be affecting investors’ decisions to sell off their stock.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
